The National Center for Toxicogenomics: using new technologies to inform mechanistic toxicology. by Tennant, Raymond W
A 8 VOLUME 110 | NUMBER 1 | January 2002 • Environmental Health Perspectives
The science of toxicology has evolved from the empirical codification
of dose-related effects to studies directed toward understanding the
mechanisms by which individual agents cause their effects in humans.
Due to technical limitations, this evolution has been relatively slow,
being accomplished one chemical or one effect at a time. To prospec-
tively use the understanding gained on the mode of action of a single
chemical, it is also necessary to know about structurally and function-
ally related chemicals and their time- and dose-dependent biological
effects. In addition to chemicals and drugs, there are a plethora of
environmental factors and stressors, such as ultraviolet and ionizing
radiation, biological agents, and dietary and lifestyle components, that
can contribute to the development of disease. The effects of all of
these agents must be characterized to a progressively greater depth for
us to understand the biochemical and genetic complexity of the cells
in which adverse effects are manifested. In this view, toxicology will
progressively develop from predominantly individual chemical studies
into a knowledge-based science in which experimental data are com-
piled and computational and informatics tools will play a significant
role in deriving a new understanding of toxicant-related disease (1). 
The application of gene expression technology to understand the
actions of chemicals and other environmental stressors on biological
systems has been catalyzed by the rapid development of genome-
based technology (2–4). The capacity to array large numbers of indi-
vidual gene fragments on small matrices that can be hybridized to
mRNA or cDNA has made it possible to synchronously assess the
variety of effects that specific chemicals can cause, both good and
bad. These technologic advances have led to the development of the
field of toxicogenomics, which proposes to apply both mRNA and
protein expression technologies to study chemical effects in biologi-
cal systems (5–11). In recognition of the unique scientific opportuni-
ties afforded by this approach, the National Institute of
Environmental Health Sciences (NIEHS) has created the National
Center for Toxicogenomics (NCT). This center’s mission is to pro-
mote the evolution and coordinated use of gene expression technolo-
gies and to apply them to the assessment of toxicologic effects in
humans. The primary goal is to provide a worldwide reference sys-
tem of genome-wide gene expression data and to develop a knowl-
edge base of chemical effects in biological systems. Such a knowledge
base will also, as a secondary goal, provide a profound understanding
of the mechanisms by which stressor-induced injury occurs.
The NCT was formally established in September 2000 and is
working to implement a strategy through which its mission can be
achieved. There is implicit recognition that the goals are long-range
and that substantial time and effort will be required to develop a
truly informative knowledge base. Due to the magnitude and com-
plexity of the science underlying these goals, a central theme of the
NCT is the formation of national and international consortia of
universities, other federal research and
regulatory agencies, and private sector
organizations. Some researchers
(10,12) have expressed concern that
the capacity to rapidly obtain large
amounts of data on chemical effects
using these technologies could result
in inappropriate decisions about the potential for chemical-induced
adverse effects. However, collective efforts such as those proposed in
the NCT partnerships will do much to help develop scientific con-
sensus on the appropriate uses of gene expression data. 
Practical matters will dominate in the early stages of the NCT.
Importantly, development of a reference database will require some
effort at achieving a consensus on content and data quality standards.
In addition, it is highly desirable that the data be preserved in a pri-
mary form so as to permit reanalysis as bioinformatics tools evolve
and improve. We must approach all of these efforts in an incremen-
tal fashion, recognizing that in the face of rapid technologic change,
it is impossible to anticipate all of the opportunities and problems
that can and will develop.
Within this incremental approach several steps can be clearly
defined. The first step is to test the hypothesis that signature profiles
of individual chemicals, drugs, and other stressors can be defined. It
is also necessary to test the hypothesis that specific toxicities will
carry signature profiles and that these profiles can be recognized
within certain dose-and-time parameters. 
The NCT is conducting a series of “proof-of-principle” experi-
ments that are designed to establish signature profiles and to link the
patterns of altered gene expression to specific parameters of well-
defined, conventional indices of toxicity. This “phenotypic anchor-
ing” of gene expression data to conventional toxic effects is necessary
to clearly demarcate pharmacologic or incidental effects from those
changes either associated with or causal of adverse effects. A learning
set of data on both pharmacologic and toxic gene expression profiles
would then allow for distinguishing and predicting adverse effects for
other well-defined compounds that could be tested under code.
These data will help to establish the use of empirical gene expression
profiles for toxicologic characterization, particularly chronic toxicity,
which has been and will continue to be a focus of the NIEHS.
Recent studies using a relatively small learning set (13–15) and
RNAs that are tested in blind studies have shown that it is possible to
identify signature expressed gene patterns (13). This is an extremely
important advance for the field and serves as the first major valida-
tion of the hypothesis that signature gene arrays can be defined and
reproduced. Because these studies were conducted on acutely
exposed animals, the array patterns appear to be representative of the
pharmacologic activity of the chemicals. One group within the NCT
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has begun to conduct further proof of principal experiments
designed to distinguish between the pharmacologic and toxicologic
effects of chemicals, and to develop a learning set of responses that
are linked to conventional phenotypic parameters of toxicity (i.e.,
hepatomegaly, hepatocellular necrosis, inflammation, etc.) (16).
These studies will take us one step closer to being able to address an
issue that is of prime importance to the National Toxicology
Program: the use of toxicogenomic approaches for understanding the
biochemical processes associated with chronic chemical exposures.
This is a particularly difficult problem but an important component
of our strategy. To address this issue, it is important to determine
whether or not serum/blood cells can be used as an alternative to
specific target organ tissue, that is, can an informative subset of the
pharmacologic and toxic parameters of acute chemical exposure seen
in target tissues also be seen in blood. We are now testing this
hypothesis, and if blood components can be used as a surrogate for
tissue-specific chemical effects, this will open the door for compara-
tive studies with exposed human populations.
One goal of the NCT is to define pathways and gene interactions
through which chemical or environmental stressor effects are mediat-
ed; the secondary goal of developing a knowledge base, including
empirical signature profiles, is equally important. One model for
achieving both goals was initiated by the development of a
Toxicogenomics Research Consortium that will work under a
National Institutes of Health cooperative agreement. The announce-
ment for development of this grant-supported consortium was divid-
ed into two components: an independent component comprising
individual research projects within the framework of a program pro-
ject grant, and a dependent component in which members of the
consortium will collaborate in the development of studies to bring
definition to toxicogenomics. In the current state of gene expression
technology, there are different methodologies for arraying genes and
for assessing mRNA expression, and different informatics tools that
are being applied to the management and analysis of such data. To
develop a substantial reference database, it will be necessary to collec-
tively define quality criteria for submission of data to the common
Chemical Effects in Biological Systems (CEBS) database and to have
the capacity to store primary array data for subsequent reanalysis.
There is another parallel consortium that is dealing with the
same platform and informatics issues and will complement the work
of the NCT. The Health and Environmental Sciences Institute of
the International Life Sciences Institute (ILSI) is coordinating the
efforts of approximately thirty pharmaceutical companies in a world-
wide effort to evaluate the harmonization of gene expression data
and analysis. The ILSI Genomics Project (17) is focusing on three
categories of toxicants: genotoxicants, hepatotoxicants, and nephro-
toxicants. One strategy that the ILSI consortium is applying involves
in-life studies conducted at specific laboratories where animals are
dosed, tissues are taken for histopathology, and RNA is extracted
and distributed to participating laboratories for microarray analysis
using methods chosen by the respective participating laboratories.
This type of collaboration will go a long way toward minimizing
problems associated with RNA extraction and quality and in provid-
ing a basis for useful comparisons of expression data from various
microarray platforms. The acquisition of tissue samples for
histopathology will make it possible to characterize the type of toxici-
ty associated with the chemical exposures at the time tissues are sam-
pled for mRNA analysis so phenotypic anchoring of the microarray
results will be possible in relationship to chemical pathology.
It is very likely that time- and dose-dependent microarray data
will be reflective of phases of chemical activity. Initial responses of
organisms or tissue to chemical exposure within 24–48 hr at doses
that are not acutely toxic may provide data on specific genes involved
in the pharmacologic action of the drug or chemical. As exposure to
the stressor or agent is increased in time or dose, toxicity or cellular
injury will become progressively obvious and various adaptive func-
tions will be expressed. The use of microarrays should thus provide
the opportunity to search for signature pathways of toxic injury. Such
data will allow insight into the mode or mechanism of toxic injury
and will also provide a means of distinguishing array patterns indica-
tive of the adverse effect of the agent. If array data can be “phenotypi-
cally anchored” to conventional indices of toxicity (histopathology,
clinical chemistry, etc.) it will be possible to search for evidence of
injury prior to its clinical or pathologic manifestation. This approach
could lead to development of early biomarkers of toxic injury, and it
may also help to resolve issues related to interspecies extrapolation
and variation in susceptibility across individuals. 
Another critical component of a toxicogenomics strategy is the
analysis of global alterations of protein expression (18). Although
mRNA analysis is a potentially powerful tool for recognizing chemi-
cal-induced effects, analysis of protein sequence, structure, and
modification provides advantages more clearly reflecting the actual
current state of activity of the cell or tissue. Promising new methods
in proteomics are emerging, including the capacity to profile pro-
teins with surface-enhanced laser desorption mass spectrometry
(19–23) and antibody arrays (24,25). Correlations between changes
in mRNA and protein levels may offer insights into the function of
genes or serve as a guide in the search for protein biomarkers of
chemical exposure and predictive toxicity. 
Another technologic innovation, called metabonomics (26),
involves the application of nuclear magnetic resonance spectroscopy
to characterize tissue-wide patterns of chemical metabolites. In con-
junction with the use of microarray and proteomic characterization,
metabonomics will be a useful adjunct to define mechanisms of
injury.
Although genome-wide alterations in either mRNA, proteins, or
metabolites in tissue extracts may be useful in identifying signature
gene changes, a critical step in verifying that the gene product(s)
plays a role in a toxic process requires localization of the target genes
and its products to specific cell types. This requires the use of in situ
hybridization, immunohistochemistry, laser capture microdissection,
and other techniques to identify the cells expressing the gene(s).
Other techniques, such as Northern or Western blotting or real-time
polymerase chain reaction, are used to verify the expressed gene or to
selectively analyze its expression over time or dose parameters. It will
also become more important to analyze expression in specific cell
populations in order to profile the alterations in gene expression
involved in chronic chemical exposure that lead to tumor develop-
ment. The capability to focus on limited cell populations is depen-
dent upon cell separation methods that will minimize the opportuni-
ty for cells to alter the patterns of genes expressed in situ. Methods
that prolong the isolation and separation of target cells will induce
adaptive responses in the cells that are not related to chemical expo-
sure. It is also dependent on high fidelity linear amplification of
mRNA, the use of array platforms that require minimal amounts of
cDNA, or proteomic methods that are highly sensitive.
At the present state of development of the field of toxicoge-
nomics, the major advances in understanding toxic effects will still
be made one chemical, agent, or mechanism at a time. However,
the promise of this new technology is such that it can be used to
generate data on large numbers of chemicals and exposure condi-
tions and to develop an unprecedented knowledge base that can be
used to guide future research, improve environmental health, and
aid in regulatory decisions. Development of the knowledge base
must proceed incrementally and requires the collective efforts of
many individuals and institutions. From the results of individual
mRNA arrays and proteomic or metabonomic analyses it is difficult
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However, as the database expands to include structurally or func-
tionally related agents and as gene identity, functional genomics,
and annotation progresses, it will be possible to search in a compre-
hensive way for common, critical, or causal changes. As it becomes
possible to create pathway maps of common cellular processes, it
will be possible to map partial genome arrays to pathways and to
link such changes to known phenotypic markers of toxicity. The
proposed databases and relational linkages must grow incrementally,
and developers and users must have the patience and dedication to
remain on course. Such incremental growth will eventually become
exponential growth, and the field of toxicology will be profoundly
changed. Given the vast numbers and diversity of drugs, chemicals,
and environmental stressors, the diversity of species in which they
act, the time and dose factors that are critical to the induction of
beneficial and adverse effects, and the diversity of phenotypic conse-
quences of exposures, it is only through the development of a rich
knowledge base and its availability to all of the scientific community
that toxicology and environmental health can rapidly advance.
Concomitant with development of the data/knowledge base must
be the evolution of informatics (computational and statistical) and
data mining tools (query algorithms, relational interfaces, etc.) and
the individuals trained to apply them (27–30).
The NCT has committed itself to the national effort to develop
a CEBS knowledge base as a long-range goal of its strategy. The
magnitude of the effort required to populate the databases that will
comprise the knowledge base requires a collective will and collabo-
rative efforts. We will continue to develop additional partnerships
with scientists in academia, the private sector, and other govern-
mental organizations to create a public knowledge base that will be
a lasting resource for the scientific community. The efforts of the
NCT can be followed on the NCT Web site (31). 
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